MODULE 1: Evolving Therapeutic Algorithms for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia (CLL) — Dr Kahl

• Implications of recent Phase III data comparing ibrutinib (with or without rituximab) to standard chemoimmunotherapy for younger (ECOG-E1912) and older (Alliance A041202) patients with treatment-naïve CLL
• Results from the Phase III CLL14 trial evaluating venetoclax/obinutuzumab versus chlorambucil/obinutuzumab for patients with treatment-naïve CLL and coexisting medical conditions; clinical implications of the recent FDA approval of this regimen
• Outcomes from the Phase III iLLUMINATE trial comparing ibrutinib/obinutuzumab to chlorambucil/obinutuzumab for treatment-naïve CLL; recent FDA approval of ibrutinib/obinutuzumab and patient selection for its use
• Clinical and biologic factors influencing the selection of first-line treatment regimen for patients with newly diagnosed CLL requiring active therapy
• Emerging results from the Phase III ELEVATE-TN trial comparing obinutuzumab/chlorambucil, acalabrutinib/obinutuzumab and acalabrutinib for patients with previously untreated CLL; recent breakthrough therapy designation for acalabrutinib as monotherapy for CLL

MODULE 2: Management of Relapsed/Refractory (R/R) CLL and Novel Investigational Approaches — Prof Gribben

• Long-term outcomes of the Phase III MURANO trial comparing venetoclax/rituximab to bendamustine/rituximab (BR) for R/R CLL
• Key findings from the Phase III ASCEND trial comparing acalabrutinib to rituximab in combination with either idelalisib or bendamustine for patients with R/R CLL; ongoing Phase III ELEVATE-RR study of acalabrutinib versus ibrutinib for high-risk R/R disease
• Key efficacy and safety outcomes from the Phase III DUO trial evaluating duvelisib versus ofatumumab for R/R CLL; FDA approval of duvelisib and optimal role of PI3 kinase inhibition in patients with R/R CLL
• Ongoing randomized trials evaluating novel combination approaches for newly diagnosed CLL (eg, FLAIR, CLL13 [GAIA], CLL3011 [GLOW])
• Potential role of minimal residual disease assessment to permit rational treatment discontinuation in patients with CLL

MODULE 3: Contemporary Management of Newly Diagnosed and R/R Follicular Lymphoma (FL) — Dr Cheson

• Clinical and research implications of the Phase III RELEVANCE trial evaluating the “R-squared” regimen of lenalidomide/rituximab in newly diagnosed FL
• Results from the Phase III AUGMENT trial comparing R-squared to rituximab monotherapy for patients with R/R indolent lymphomas; recent FDA approval of R-squared for previously treated FL and marginal zone lymphoma
• Role of obinutuzumab-based induction and maintenance therapy for previously untreated FL; integration of obinutuzumab into current algorithms for treatment-naïve and R/R disease
• Mechanistic similarities and differences between the commercially available PI3 kinase inhibitors copanlisib, duvelisib and idelalisib; patient selection for these agents
• Ongoing investigation of novel agents in FL (eg, acalabrutinib, venetoclax)

MODULE 4: Protocol and Off-Protocol Care for Patients with Mantle Cell Lymphoma (MCL) — Dr Abramson

• Early activity and safety data with ibrutinib alone or in combination with other systemic therapies for previously untreated MCL; ongoing and planned Phase III trials (eg, TRIANGLE, SHINE, SYMPATICO)
• Clinical research data supporting the FDA approval of acalabrutinib in R/R MCL and patient selection for this approach in routine practice
• Early activity, ongoing trials and current nonresearch role, if any, of venetoclax in R/R MCL
• Rates of clinical and laboratory tumor lysis syndrome documented in patients with non-Hodgkin lymphoma receiving venetoclax; comparison to historical studies of venetoclax in CLL
• Other promising agents and strategies under investigation in the front-line and R/R settings

MODULE 5: Recent Breakthroughs and Other Promising Approaches in the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Sehn

• Clinical and research implications of trials evaluating lenalidomide-containing combination regimens for patients with DLBCL
• Published findings from the Phase III PHOENIX study of ibrutinib in combination with R-CHOP for previously untreated nongerminal center B-cell DLBCL; variability of efficacy outcomes according to patient age and implications for future research
• Available efficacy and safety data leading to the FDA approval of polatuzumab vedotin in combination with BR for patients with R/R DLBCL; optimal incorporation into current management algorithms
• Early findings with polatuzumab vedotin in combination with R-CHP for patients with previously untreated DLBCL; ongoing Phase III POLARIX trial
• Other promising agents or strategies under investigation for newly diagnosed and relapsed/refractory DLBCL (eg, venetoclax, tafasitamab)

MODULE 6: Integration of CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy into the Management of Lymphomas — Dr Nastoupil

• Compositional and mechanistic similarities and differences between available (axicabtagene ciloleucel [axi-cel], tisagenlecleucel [tis-cel]) and investigational (lisocabtagene maraleucel [liso-cel]) CD19-directed CAR T-cell platforms with established efficacy in DLBCL
• Longer-term follow-up from clinical trials establishing the efficacy and safety of axi-cel, tis-cel and liso-cel
• Patient identification and appropriate referral for consideration of CAR T-cell therapy
• Current understanding of potential clinical and biologic factors predictive of response or toxicity to CAR T-cell therapy in patients with DLBCL or other aggressive lymphomas
• Available data with and ongoing evaluation of CD19-directed CAR T-cell therapy in CLL and other lymphoma variants (eg, FL, MCL)